Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis
| Autor: | David Waterson, Vijender Panduga, Gajanan Shanbhag, Jim Werngren, Sheshagiri Gaonkar, Manjunatha R, Gulebahar Sheikh, Prashanti Madhavapeddi, Reetobrata Basu, Kakoli Mukherjee, Radha Shandil, Jitendar Reddy, Vrinda Nandi, Mahesh Kumar, Suresh Solapure, Venkita Subbulakshmi, Anirban Ghosh, Disha Awasthy, Praveena Manjrekar, Jon Read, Meenakshi Balganesh, Abhijeet Deshpande, Vaishali Humnabadkar, Anand Kumar V. Raichurkar, Sven Hoffner, Helen H.J. McMiken, Shahul Hameed P, Vasan K. Sambandamurthy, Sreevalli Sharma, Jayashree Puttur, Murugan Chinnapattu |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Antitubercular Agents
DNA gyrase Microbiology Cell Line Mycobacterium tuberculosis Mice Structure-Activity Relationship Structure–activity relationship Animals Humans Tuberculosis Pharmacology (medical) Experimental Therapeutics Mode of action chemistry.chemical_classification Pharmacology biology Errata Mycobacterium smegmatis Point mutation biochemical phenomena metabolism and nutrition biology.organism_classification bacterial infections and mycoses Enzyme Infectious Diseases chemistry Biochemistry DNA supercoil bacteria |
| Zdroj: | Antimicrobial agents and chemotherapy. 58(1) |
| ISSN: | 1098-6596 |
| Popis: | Moxifloxacin has shown excellent activity against drug-sensitive as well as drug-resistant tuberculosis (TB), thus confirming DNA gyrase as a clinically validated target for discovering novel anti-TB agents. We have identified novel inhibitors in the pyrrolamide class which kill Mycobacterium tuberculosis through inhibition of ATPase activity catalyzed by the GyrB domain of DNA gyrase. A homology model of the M. tuberculosis H37Rv GyrB domain was used for deciphering the structure-activity relationship and binding interactions of inhibitors with mycobacterial GyrB enzyme. Proposed binding interactions were later confirmed through cocrystal structure studies with the Mycobacterium smegmatis GyrB ATPase domain. The most potent compound in this series inhibited supercoiling activity of DNA gyrase with a 50% inhibitory concentration (IC 50 ) of M. tuberculosis H37Rv, and an MIC 90 of M. tuberculosis . The frequency of isolating spontaneous resistant mutants was ∼10 −6 to 10 −8 , and the point mutation mapped to the M. tuberculosis GyrB domain (Ser208 Ala), thus confirming its mode of action. The best compound tested for in vivo efficacy in the mouse model showed a 1.1-log reduction in lung CFU in the acute model and a 0.7-log reduction in the chronic model. This class of GyrB inhibitors could be developed as novel anti-TB agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|